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ABSTRACT Estimation of comparative disease burden in epidemiological surveys is complicated by the fact that high
comorbidities exist among many chronic conditions. The easiest way to take comorbidity into consideration is to distinguish
between pure and comorbid conditions and to evaluate the incremental effects of comorbid conditions in prediction equa-
tions. This approach is illustrated here in an analysis of the effects of pure and comorbid major depression (MD) and
generalized anxiety disorder (GAD) on a number of different measures of role impairment in the US National Comorbidity
Survey (NCS) and the Mental Health Supplement to the Ontario (Canada) Health Survey (the Supplement). Pure MD
and pure GAD were found to have roughly equal independent associations with role impairments. The incremental effects
of having comorbid MD and GAD were found to vary depending on the outcome under investigation. The paper closes
with a discussion of the methodological complexities associated with generalizing to comorbidities that involve rare conditions
or more than two disorders.
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Background
It is widely known that a number of different physical
disorders (Verbrugge and Patrick, 1995; Stewart,
Greenfield and Hays, 1989) and mental disorders
(Ormel, Von Korff, Üstün, Pini, Korten and
Oldehinkel, 1994; Ormel, Kempen, Deeg, Brilman,
Van Sonderen and Relyveld, 1998) cause role impair-
ments. Some of these impairments have substantial
implications for the economy, such as the $17 billion
average salary-equivalent work absenteeism in the US
estimated to be caused by major depression
(Greenberg, Stiglin, Finkelstein and Berndt, 1993).
Results such as these have led to an interest among
health-policy researchers in the possibility that
expanded outreach and guideline-concordant treat-
ment of impairing chronic conditions might represent
an investment opportunity for employers (Kessler,
Greenberg, Mickelson, Meneades and Wang, 2001) as
well as for governments (Murray and Lopez, 1996). 
The World Health Organization (WHO) Global
Burden of Disease (GBD) Study is the most ambitious
attempt to estimate the comparative burdens of many
different diseases. These estimates were obtained by
combining estimated prevalences from community
epidemiological surveys with estimated impairments
from the ratings made by expert raters. A methodological
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problem with this procedure, as well as with much of
the related research carried out and the broader litera-
ture on illness-related role impairments, is the lack of
attention to comorbidity. Many people with chronic
conditions suffer from more than one disorder (Dewa
and Lin, 2000). Pure disorders are, in general, much
less impairing than comorbid disorders in clinical
samples (Ormel et al., 1994). Comorbidities of mental
disorders with commonly occurring chronic physical
disorders are of special importance as a number of such
comorbidities have been documented in both general
population samples (Neeleman, Ormel and Bijl, 2001)
and in primary care samples (Berardi, Berti Ceroni,
Leggieri, Rucci, Üstün and Ferrari, 1999). Clinical
studies have also found excess impairment associated
with mental-physical comorbidities (Sullivan, La
Croix, Russo and Walker, 2001). 
It is possible to address this problem empirically in
epidemiological surveys that collect information on a
wide range of disorders and assess impairments indepen-
dently of the disorders (to obtain information on actual
impairments rather than respondent reports of their
perceptions regarding the separate impairments associ-
ated with each of their illnesses). The impairments
associated with pure disorders can be compared empiri-
cally in such studies, adjusting for possible confounding
variables, to generate a rank ordering of pure effects.
Comparisons of the incremental increases in impair-
ments associated with comorbid disorder clusters versus
pure disorders can also be compared to determine
whether the effects of specific disorders vary depending
on the presence or absence of other disorders. 
The present report illustrates this approach by
examining the separate and joint effects of major
depression (MD) and generalized anxiety disorder
(GAD) on role impairment. MD-GAD comorbidity is
of special interest in this regard both because MD was
rated as one of the most burdensome diseases in the
world by the GBD investigators (Murray et al., 1996)
and because MD is known to be highly comorbid with
GAD (Kessler, Andrade, Bijl, Offord, Demler and
Stein, in press). Indeed, the comorbidity of GAD with
MD is so high in some clinical studies that several
commentators have suggested that GAD might be a
subtype of MD rather than an independent disorder
(Brawman-Mintzer, Lydiard, Emannuel, Payeur,
Johnson, Roberts, Jarrell and Ballenger, 1993; Brown,
Barlow and Liebowitz, 1994; Gorman, 1996; Roy-
Byrne, 1996).
The controversy about the diagnostic status of
GAD illustrates one important advantage of communi-
ty epidemiological studies over clinical studies of
comorbidity: help-seeking bias sometimes associated
with comorbidity is removed when analysis is based on
community studies. In the case of comorbid MD-GAD,
community epidemiological studies that compared
respondents who sought treatment with those who did
not seek treatment have shown that the estimated
comorbidity of GAD with MD is spuriously inflated in
treatment samples because comorbid MD is a strong
predictor of help seeking among people with GAD
(Wïttchen, Zhao, Kessler and Eaton, 1994). 
Methods
Study populations
The data come from the US National Comorbidity
Survey (NCS) (Kessler, McGonagle, Zhao, Nelson,
Hughes, Eshleman, Wïttchen and Kendler, 1994) and
the Mental Health Supplement (the Supplement) to
the Ontario Health Survey (OHS) (Offord, Boyle,
Campbell, Cochrane, Goering, Lin, Rhodes and Wong,
1994). Both surveys were carried out in 1990 using a
psychiatric interview that assessed a core set of disorders
using identical questions about symptoms and impair-
ments. The NCS is a nationally representative survey
that was administered in face-to-face in-home inter-
views to a sample of 8,098 persons aged 15 to 54 in Part
I. The response rate was 82.4%. Part II of the NCS was
a series of questions about risk factors and consequences
of mental illness administered to a subsample of 5,877
respondents consisting of all those who screened posi-
tive for mental disorder in the Part I interview and a
random subsample of others. The data on role impair-
ments reported here are from the Part II subsample and
are weighted to adjust for differential probabilities of
selection and non-response. The Supplement is a repre-
sentative survey of residents of Ontario that was
administered to a follow-up sample of 9,953 respondents
aged 18 and above who were randomly selected from
those living in households that participated in one quar-
terly replicate of the OHS. The OHS response rate in
the Supplement replicate was 88.1% and, in these
households, 76.5% participated in the Supplement, for
an overall response rate of 67.4%. In order to have a
comparable age range across the two surveys, the current
analysis is limited to the 7,340 Supplement respondents
who were age 18–54 at the time of interview.
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Diagnostic assessment
Diagnoses are based on a modified version of the
Composite International Diagnostic Interview (CIDI)
(World Health Organization, 1990), a fully structured
interview designed to be administered by interviewers
who are not clinicians and to generate diagnoses
according to the definitions and criteria of both
Diagnostic and Statistical Manual of Mental
Disorders, Third Edition, Revised (DSM-III-R)
(American Psychiatric Association, 1987) and the
International Classification of Diseases (ICD-10)
(World Health Organization, 1991). The current
report uses DSM-III-R criteria. Although the focus is
on the prevalences of GAD and MD within the 30
days prior to interview, we also control for 30-day
prevalences of the other disorders assessed in the 
surveys. These include other anxiety disorders 
(panic disorder, simple phobia, social phobia, agora-
phobia, and post-traumatic stress disorder), mania,
substance-use disorders (alcohol and drug abuse and
dependence), and, in the NCS, non-affective psy-
chosis (NAP). Diagnoses are made without hierarchy
rules. An NCS clinical reappraisal study found good
test-retest reliability and procedural validity of all the
diagnoses compared to clinical reassessments (Kessler,
Wïttchen, Abelson, McGonagle, Schwarz, Kendler,
Knäuper and Zhao, 1998), with the exceptions of
mania and NAP. Cases of mania were limited to those
with a euphoric-grandiose symptom profile, based on
the finding that the CIDI only validly assesses this
subtype (Kessler, Rubinow, Holmes, Ableson and
Zhao, 1997). Based on the finding that the CIDI sub-
stantially overdiagnoses NAP (Kendler, Gallagher,
Abelson and Kessler, 1996), cases of NAP were limit-
ed to those identified in clinical reinterviews. These
clinical reinterviews were carried out with all NCS
respondents who screened positive for NAP with the
CIDI. 
The DSM diagnostic hierarchy rule for GAD and
MD stipulates that an episode of generalized anxiety
that occurs exclusively within a major depressive
episode is not classified as GAD. This rule was opera-
tionalized in the NCS and the Supplement in a series
of three questions asked of all respondents who 
met criteria for both GAD without hierarchy and 
MD. The first asked whether the GAD never, some-
times, or always occurs during times when the respondent
is depressed. If sometimes or always, the respondent is
asked which syndrome starts first during these episodes
of overlapping symptoms – the depression, the anxiety,
both at the same time, or whether it varies. The third
question was similar to the second except that it asked
which symptoms end first, when and if either of them
ever resolves. Of the 54 respondents in the two surveys
combined who met criteria for 30-day comorbid 
GAD without hierarchy, only three reported that 
their episodes of GAD occurred exclusively within their
episodes of MD and the majority of the others reported
both that the GAD usually starts first and that the MD
usually resolves first.
Measures of role impairment
Respondents in both surveys were asked how many
days in the past 30 they were ‘totally unable to work
or carry out your normal daily activities’ because of
problems with their physical or mental health and, if
any, how many of these disability days were due to
problems with their emotions, nerves, or mental
health. Respondents were then asked how many days
in the past 30, exclusive of these disability days, they
had to ‘cut back on the amount of time you worked or
not get as much done as usual’ because of problems
with their physical or mental health and, if any, how
many of these cutback days were due to problems with
their emotions, nerves, or mental health. This report
focuses on the prevalences of disability and cutback
days due to emotions, nerves, or mental health, 
collectively referred to as impairment days or role
impairment.
Analysis procedures
Cross-tabulations were used to estimate the overlap
between 30-day GAD and MD. Cross-tabulations and
calculations of subsample means were then used to
study the associations of pure and comorbid GAD and
MD with role impairments. Multiple linear regression
analysis was then used to estimate the associations of
GAD and MD with role impairments. All regression
equations were controlled for sociodemographic 
variables (age, gender, education, race-ethnicity,
employment status, marital status, urbanicity and, in
the US, region of the country) as well as for the other
DSM-III-R mental and substance use disorders assessed
in the surveys. Equations were estimated for the sepa-
rate and joint effects of MD and GAD on the
outcomes.
Both surveys were based on multistage area proba-
bility samples that featured geographic clustering and
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weighting to correct for differential probabilities of
selection. Design-based methods were consequently
required to estimate significance tests. The method
used in all tests reported in this paper is the method of
jackknife repeated replication (Kish and Frankel,
1974). This method uses repeated subsampling to
generate empirical distributions of coefficients of inter-
est. All evaluations of statistical significance were
made at the 0.05 level using two-sided tests.
Results
The prevalences and comorbidity of 30-day GAD 
and MD 
As shown in Table 1, the 30-day prevalences (with
standard errors in parentheses) of GAD are 1.5% (0.2)
in the US and 0.6% (0.0) in Ontario, and the 30-day
prevalences of MD are 4.6% (0.4) in the US and 1.9%
(0.1) in Ontario. A substantial proportion of respon-
dents with 30-day GAD in both the US (40.2%) and
Ontario (36.8%) also have 30-day MD, whereas 12.9%
of the respondents with MD also have GAD in the US
and 11.4% in Ontario. 
The impairments associated with independent and comorbid
GAD and MD
Scores on the measures of impairment are presented in
Table 2. Four results are noteworthy. First, the role
impairments associated with comorbid GAD and MD,
GAD only, and MD only are all substantially higher
than those found among respondents who have neither
GAD nor MD (statistically significant at the 0.05 level
in 31 of 36 comparisons). The prevalences for any dis-
ability, any cutback, or any disability or cutback range
between 1.0% and 5.9% among respondents with nei-
ther MD nor GAD compared to a range between 4.3%
and 63.1% among respondents with one or both of
these disorders.
Second, comparing those with GAD only to those
with MD only shows no consistently higher impair-
ment for one disorder than the other. Five of the 12
comparisons are statistically significant at the 0.05
level, with two showing more impairment for GAD
than MD, and the other three showing higher impair-
ment for MD than GAD.
Third, a comparison of results in the first column of
the table with later columns shows that 30-day 
prevalences of any disability days (full days of role
impairment), any cutback days (days of partial 
role impairment), and any days of either disability or
cutback are more prevalent among respondents with
30-day comorbid GAD and MD (12.6% to 63.1%)
than among those with either GAD only (4.3% to
34.5% – statistically significant difference in five of six
comparisons) or MD only (14.2% to 36.3% – statisti-
cally significant difference in three of six comparisons)
in both surveys. The only exception is that the preva-
lence of any disability days in Ontario is significantly
lower among respondents with comorbid GAD and
MD (12.6%) than those with either GAD only
(20.2%) or MD only (18.6%). The same general
pattern holds for the ‘number/any’ columns in Table 2,
Table 1. Thirty-day prevalences and comorbidity of DSM-III-R generalized anxiety disorder (GAD) and major depression in
the two surveys1
United States Ontario
% (se) % (se)
Generalized anxiety disorder (GAD) 1.5% (0.2) 0.6% (0.0)
Major depression (MD) 4.6% (0.4) 1.9% (0.1)
MD among among those with GAD 40.2% (5.4) 36.8% (2.4)
GAD among those with MD 12.9% (2.3) 11.4% (1.4)
(n) (5877) (7340)
1 GAD requires a minimum duration of six months. Thirty-day prevalence consequently means that respondents have been in
an episode during the past 30 days and that the hierarchy rules, with the stipulation that the classification of MD but not GAD
(MD Only) was given to the small number of respondents who reported that all their episodes of GAD occurred exclusively
within episodes of MD (the MD started prior to the GAD and remitted after GAD).
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which show the average (mean) number of 30-day
role-impairment days among respondents who reported
any impairment. A comparison across subsamples
shows that these average frequencies are consistently
higher for respondents with comorbid GAD and MD
(11.7 to 24.1 days) than for respondents with MD only
(4.7 to 12.8 days – statistically significant difference in
five of six comparisons) in both surveys and for respon-
dents with GAD-Only in the U.S. (7.2 to 10.7 –
statistically significant difference in two of three
comparisons) but not Ontario (6.2 to 30.0 – no statisti-
cally significant differences). 
Fourth, a rough evaluation of the incremental
effects of MD over GAD and of GAD over MD can be
made by comparing
• the sum of the increases in the outcomes associated
with pure disorders (MD only or GAD only versus
neither) with
• the increase associated with comorbidity (GAD
and MD versus neither).
For example, in the first row of Table 2, we see that
GAD only and MD only are associated with 3.8% and
12% increases respectively, in proportion with any dis-
ability compared to neither MD nor GAD.
Generalized anxiety disorder and MD, in comparison,
is associated with a 38.5% increase compared to nei-
ther MD nor GAD. As 38.5% is greater than the sum
of 3.8% and 12.0%, this suggests that the effect of
comorbid MD and GAD is ‘greater than the sum of its
parts’ with regard to this outcome.
A formal significance test of whether the effect of
comorbid MD and GAD is greater than the sum of its
parts can be made using regression analysis with interac-
tion terms. It is important to note, however, that the
existence of a statistically significant interaction is depen-
dent on the model used to describe the data (Kraemer,
Stice, Kazdin, Offord and Kupfer, 2001). For example, an
interaction in a model that assumes linear associations
(such as an ordinary least-squares linear regression 
equation) evaluates the difference between the observed
value of the outcome among people with comorbidity
compared to the sum of the linear effects of the pure disor-
ders, whereas an interaction in a model that assumes
multiplicative associations (such as a logistic regression
equation) evaluates the effect of comorbidity in relation
to the product of the linear effects of the pure disorders
(Rothman, Greenland and Walker, 1980).
The independent and joint effects of GAD and MD in
predicting role impairments
Results of linear regression analyses for the effects of
independent and comorbid GAD and MD in predict-
ing 30-day role impairments are reported in Table 3.
The equations controlled for a variety of socio-
demographic variables (age, gender, employment status,
marital status, urbanicity and, in the US, region of the
country and race-ethnicity) and for the other DSM-
III-R disorders assessed in the surveys. To the extent
that these control variables mediate the effects of MD
and GAD on the outcomes, they might represent over-
controls. However, we felt that it was important to err
on the side of presenting lower bound estimates rather
than risk the possibility of incorrectly interpreting
effects actually due to these controls as being due to
MD or GAD.
The results in the first column show that, in the
subsample of respondents without 30-day MD, 30-day
GAD is consistently associated with elevated role
impairments in both the US and Ontario (four of six
coefficients statistically significant) compared to
respondents without GAD. These effects are in the
range of 1.5 to 5.6 excess disability and/or impairment
days. Importantly, these effects hold after controlling
for sociodemographic variables and for the other 
DSM-III-R disorders assessed in the surveys. Results in
the next column show parallel effects for MD in the
subsample of respondents without GAD. There is a
consistent elevation of role impairments in both the
US and Ontario (six of six coefficients statistically
significant) compared to respondents without MD,
with excess impairment days in the range 0.4 to 3.7.
The results in the next column compare the impair-
ments associated with GAD without MD versus those
associated with MD without GAD. There is no consis-
tent pattern to these results, which means that the
impairments associated with these two disorders are
comparable in magnitude. None of the six coefficients
is statistically significant at the .05 level. 
The last columns of the table show that the effects of
GAD and MD are cumulative. Focusing first on GAD,
the results show fairly consistent evidence that GAD is
associated with an incremental increase in role impair-
ment among respondents with MD. Five of the six
coefficients in this column are greater than zero (indi-
cating an increase in impairment associated with
GAD) and four are statistically significant at the 0.05
level, with coefficients in the range 2.2–4.7 days. All
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six coefficients are also positive (four of six statistically
significant) in evaluating the incremental effect of MD
on impairment among respondents with GAD, with
coefficients in the range 3.6–10.2 days.
We can also evaluate, finally, whether comorbidity
has effects that are equal to the sum of its parts, greater
than the sum of its parts, or less than the sum of its
parts. As noted above, this can be done for a linear
specification by estimating a linear regression equation
that includes both main effects of MD and GAD and
an interaction between the two in predicting the
outcome. It is also possible to evaluate linear effects on
dichotomous outcomes (Rothman et al., 1980). When
the interaction is significant, it means that either
• the effect of GAD varies depending on the pres-
ence or absence of MD – a difference that can be
evaluated by comparing the coefficients in the first
column of the table (GAD without MD) with
those in the fourth column (GAD over and above
MD), and/or
• the effect of MD varies depending on the presence
or absence of GAD – a difference that can be eval-
uated by comparing the coefficients in the second
column (MD without GAD) with those in the fifth
column (MD over and above GAD).
Three of the six comparisons of the first type are 
statistically significant in Table 3. Two of these three
show that the effect of GAD is less in the presence
than the absence of MD (disability days in Ontario and
the sum of disability and cutback days in Ontario),
whereas the third shows that the effect of GAD is
greater in the presence of MD than in its absence 
(disability days in the US). Two of the six comparisons
of the second type are statistically significant, both of
them showing that the effect of MD is greater in the
presence than the absence of GAD (cutback days in
Ontario and disability and cutback days in Ontario). 
Discussion
Consistency with previous research 
The results reported here are similar to those of previ-
ous studies in general population (Robins, Locke and
Regier, 1991; Kendler, Walters, Neale, Kessler, Heath
and Eaves, 1995), primary care (Sherbourne, Jackson,
Meredith, Camp and Wells, 1996; Olfson, Fireman,
Weissman, Leon, Sheehan, Kathol, Hoven and Farber,
1997), and mental health specialty samples (Shores,
Glubin, Cowley, Dager, Roy-Byrne and Dunner, 1992;
Pini, Cassano, Simonini, Savino, Russo and
Montgomery, 1997) in showing that MD is more
prevalent than GAD and that there is strong comor-
bidity between GAD and MD. However, the
comorbidity between GAD with MD found here is a
good deal lower than in treatment studies due to the
help-seeking bias noted in the introduction. 
The observation that the majority of people with
current GAD do not have current MD, when
combined with three additional findings by other
investigators, has implications for the controversy
mentioned in the introduction regarding whether
GAD is an independent disorder or only a subtype of
MD. The first of these three findings is that symptom
profiles of GAD and MD can be distinguished in
patient samples by the relative importance of positive
affectivity (higher in GAD), negative affectivity
(higher in MD), and autonomic suppression (higher in
GAD) (Clark, Beck and Beck, 1994; Brown, Chorpita
and Barlow, 1998). The second finding is that the
sociodemographic predictors of MD and GAD are
significantly different in community epidemiological
surveys (Skodal, Schwartz, Dohrenwend, Levav and
Shrout, 1994). The third finding comes from twin
studies, which show that the environmental determi-
nants of GAD and MD are distinct (Kendler, Neale,
Kessler, Heath and Eaves, 1992). 
It is important to note, in mentioning the results of
twin studies, that these studies also suggest that GAD
and MD share similar genetic determinants (Kendler
et al., 1992). This could be construed to mean that the
two syndromes are different manifestations of the same
underlying disorder, but differ in their presentation
because of environmental factors. However, this inter-
pretation can be challenged because the genetic model
on which this conclusion is based assumes implausibly
that the joint effects of genes and environment are
additive. Such a model presupposes that the effects of
environmental determinants of GAD and MD are not
influenced by the presence or absence of genetic
predispositions to the two disorders. A more realistic
interactive model might well show differentiation of
genetic effects. Unfortunately, this latter possibility
cannot be tested with conventional twin data.
However, data from family studies have shown differ-
ential aggregation of mental disorders in the families of
patients with GAD and MD (Merikangas, Risch and
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Weissman, 1992; Reich, 1993), raising the intriguing
possibility that comorbid GAD and MD might be a
distinct disorder from either pure GAD or pure MD
(Reich, 1995).
Our finding that impairments associated with GAD
only are equivalent to those associated with MD only
differs from two recent studies of primary care samples,
which found that pure GAD is not associated with
significant impairment (Olfson et al., 1997; Schonfeld,
Verboncoeur, Fifer, Lipshutz, Lubeck and Buesching,
1997). However, these primary care studies included
very few respondents with pure GAD, introducing
substantial instability into the findings. The fact that
there is inconsistency of results across studies suggests
that this issue should be re-examined in other available
datasets.
Substantive implications
Based on the results reported here, it appears that a
substantial proportion of GAD cases in the general
population occur independently of MD and that the
role impairment due to GAD is comparable to that due
to MD even after adjusting for a wide range of other
comorbid disorders. It is important to point out that
this result holds up when we control for the presence
of other DSM-III-R disorders. This implies that GAD
is consequential in and of itself and that the impair-
ment associated with GAD is not due to MD. It is also
important to note that the magnitude of impairment is
substantial. In the absence of MD, GAD is associated
with an average of between 1.5 and 5.4 days of role
impairment per month after taking into consideration
any impairments that might be due to other comorbid
DSM disorders.
The incremental effects of GAD among people who
also have MD are similar in magnitude (2.6 to 4.7
days) to the incremental effects of MD over GAD.
Effects as large as these are in the range that has been
found in other studies for such chronic conditions as
ulcers, arthritis, and autoimmune disease (Kessler,
Greenberg, et al., 2001). The results of this study
suggest that GAD should be recognized as an impor-
tant, seriously impairing disorder that is equivalent in
impact to some of the most burdensome diseases in the
world today. 
Methodological implications
The substantive conclusion at the end of the last 
paragraph assumes, perhaps incorrectly, that the effects
of GAD only in these two surveys are, in fact, due to
GAD rather than to some other comorbid disorder
that we failed to measure. It is not possible to evaluate
this assumption in the two surveys considered here
because they did not include comprehensive assess-
ments of the many chronic physical diseases that have
been shown to be significantly comorbid with either
MD or GAD (Berardi et al., 1999; Hansen, Fink,
Frydenberg, Oxhoj, Sondergaard and Eriksen, 2001). It
would not be difficult, in principle, to focus on respon-
dents with pure MD and pure GAD, defined as these
disorders in absence of a great many other mental and
physical conditions, in a survey that included a com-
prehensive assessment of all such conditions. As a
practical matter, though, such a survey would have to
be extremely large in order to yield stable estimates of
the impairments associated with truly pure conditions
because both MD and GAD are likely to have
extremely high rates of comorbidity with at least one
other physical or mental disorder. Even in the NCS,
which contained only a superficial checklist of com-
monly occurring chronic physical conditions, more
than 90% of the respondents with MD and more than
95% of those with GAD met criteria for at least one
other lifetime physical or mental disorder. 
Three strategies are available to deal with this type
of high comorbidity. One, as noted in the last para-
graph, is to work with a very large sample in an effort
to have enough cases of pure disorders for stable 
estimation of effects on impairment. Although this is
the ideal strategy, it is important to recognize that the
proportion of respondents who continue to be classi-
fied as pure will decrease as the number of disorders
under consideration increases. The number of pure
cases of some highly comorbid disorders will conse-
quently be very small, even in large samples. In the
NCS, for example, not a single respondent with bipo-
lar disorder was found not to meet criteria for at least
one of the other mental (excluding MD) or physical
disorders assessed in the survey.
A second strategy that can be used in such cases is
to abandon the goal of working with pure disorders and
to focus instead on commonly occurring comorbid
disorder profiles. Such profiles can be discovered either
by simple enumeration and inspection or by using any
number of dimensional reduction strategies. In some
cases it might be possible to use a profiling approach to
isolate comorbid disorders that are not impairing in
themselves and to conceptualize respondents whose
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comorbidities consist entirely of these non-impairing
disorders as being ‘essentially pure’ with regard to the
effects of other disorders. In the NCS, for example,
there are a great many respondents with comorbid
profiles that consist entirely of a specific phobia and
one other disorder. As most specific phobias are associ-
ated with little, if any, serious role impairment, these
respondents might be considered to have essentially
pure disorders of other types.
A third strategy is to use multivariate analysis to
develop approximate estimates of pure disorder effect
sizes by statistically controlling for the effects of other
disorders. This is the approach used in the current
report. It is the least desirable of the three approaches
because it usually requires the researcher to assume
that the joint effects of comorbid conditions are addi-
tive. This is the key assumption that we seek to
evaluate, rather than to assume, in empirical studies of
the effects of comorbid disorders on impairment.
When sample sizes are small, it is not possible to evalu-
ate this assumption at all. When sample sizes are
somewhat larger, as in the surveys considered here, a
mixed strategy might be used in which a small subset of
disorders is taken as the focus of attention (for exam-
ple, MD and GAD) and the pure effects on
impairment of the individual disorders in this set that
occur in the absence of the others in the set can be
approximated by introducing additive controls for the
other disorders in multivariate prediction equations.
There is also a question of how to evaluate the
effects on role impairment of commonly occurring
comorbidity profiles. The MD-GAD example was so
simple, involving as it did only two disorders, that the
considerations involved in evaluating more complex
multivariate comorbidities were not illustrated. Latent
class analysis, grade of membership analysis, and other
methods of detecting multivariate disorder profiles
show that a number of disorder profiles exist that
include three, four, five, or even more mental disorders
(Kessler, 1997), physical disorders (Dewa et al., 2000),
or combinations of mental and physical disorders
(Neeleman et al., 2001). 
Is there something synergistic about these disorder
profiles so that amounts of impairment than are signifi-
cantly different from what one would expect based on
the summation of the linear effects of the component
disorders? This question can be answered by analysing
data from the sub-sample of respondents consisting of
those who either have
• no disorder;
• one and only one of the pure (or ‘essentially pure’)
disorders that define the comorbid profile; or
• the full set of disorders that define this profile.
The analysis should include a separate dummy predic-
tor variable for each of the component disorders
(coded 1 both for respondents with the pure disorder
and for respondents with the comorbid profile), an
additional dummy variable for respondents with the
comorbid disorder profile, and appropriate controls for
potential confounding variables. Synergy is established
(assuming that the linearity assumption of the model
holds) if the regression coefficient associated with 
the dummy variable for the profile is statistically 
significant. 
Two observations about this approach warrant
comment. These observations are based on our explo-
rations of data from the NCS and other large-scale
population surveys using this approach (Kessler,
Greenberg et al., 2001; Kessler, Mickelson, Barber and
Wang, 2001). First, we find that what might be called
‘negative synergy’ is a dominant tendency in such data.
For example, the impairment associated with a profile
made up of five individually impairing conditions is
usually less than five times as great as the impairment
associated with any one of the pure conditions. This
tendency is most clearly seen in a multivariate regres-
sion equation that includes a separate dummy variable
for each of a large number of individual disorders plus a
series of summary dummy variables for respondents
with exactly two of these disorders, exactly three,
exactly four, and so forth. The summary dummy 
variables almost always have negative coefficients that
increase in magnitude as the number of disorders
increases, indicating that people with multivariate
disorder clusters generally have less impairment than
expected on the basis of an additive model. 
Second, it is important not to confuse the signifi-
cance of associations among chronic conditions with
the significance of interactions involving these condi-
tions in predicting impairment. The fact that two
conditions are highly related to each other, as MD and
GAD are, tells us nothing about whether the joint
effects of these conditions on role impairment will be
additive versus synergistic. As we saw in the analyses
reported in this paper, there is no evidence of positive
synergy between MD and GAD in predicting role
impairment despite a strong relationship of the two
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disorders with each other. There is an extremely strong
synergy, in comparison, between blindness and deaf-
ness in predicting impairment even though these two
conditions are not strongly related to each other. The
search for synergy of effects, then, should not rely on
evidence regarding empirical associations among
conditions but should, instead, rely on conceptual
reasoning about the sorts of functions that are limited
by different conditions and the extent to which the
joint occurrence of impairments across these function-
al domains might combine to create synergistic
influences. 
Future directions
The World Health Organization’s World Mental
Health (WMH) surveys are currently being carried out
in over 30 countries around the world (Kessler and
Üstün, 2000). The total expected sample size of WMH
across all these countries is in excess of 250,000 cases.
One of the main goals of WMH is to estimate the
effects of individual physical and mental disorders on
current role functioning. To this end, the WMH inter-
view schedule includes a detailed chronic physical
conditions checklist in addition to an in-depth assess-
ment of a wide range of mental disorders and substance
disorders. The WHO Disability Assessment Schedule
(WHO-DAS; Rehm, Üstün, Saxena, Nelson,
Chatterji, Ivis and Adlaf, 1999) is being used to mea-
sure role impairment. 
Our hope is that the extremely large sample size of
the combined WMH surveys will yield a large enough
number of respondents with pure disorders to allow
direct estimates to be made of the impairments associat-
ed with the vast majority of the disorders assessed in the
surveys. Sensitivity analyses of these estimates will be
carried out to evaluate the consistency of aggregate 
estimates for individual disorders across countries and
the consistency of relative estimates among sociodemo-
graphic subsamples pooled across countries. In cases
where too few pure cases exist to allow direct estimates
to be made, careful analyses of commonly occurring
comorbid profiles will be carried out to see if we can
develop ‘essentially pure’ subsamples. If so, these
subsamples will be used in the same way as we would use
genuinely pure cases to generate proxy estimates of 
pure disorder effects. In cases where ‘essentially pure’
subsamples of highly comorbid disorder cannot be
found, we will work with comparisons of commonly
occurring comorbid profiles in the ways described above.
Our analyses of synergy in the WMH surveys will
focus initially on commonly occurring comorbidities,
with a special emphasis on mental-physical comorbidi-
ties. The goal here will be to make preliminary
evaluations of the likely effects on role functioning of
interventions aimed at detecting and successfully treat-
ing comorbid mental disorders among patients in
treatment for seriously impairing chronic physical
disorders. Subsequent analyses will turn to a more
comprehensive search for positively synergistic 
comorbidities and an investigation of whether there
are any key conditions that account for a number of
these effects. Such conditions, if they could be found,
would have great public health importance even if
they were associated with low impairment as pure
disorders. Given that the analyses needed to search for
such synergies will necessarily be exploratory, it will be
important to take great care to cross-validate results
both across different geographic regions of the world
and, within regions, across important sociodemograph-
ic sectors of the population. 
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